Allogenic Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant of Hematological Malignancies

Claudio Anasetti, M.D. and Benjamin Djulbegovic, M.D.
Moffitt Cancer Center
University of South Florida

Objectives:
This presentation from the Moffitt Cancer Center, University of South Florida, compares stem cell sources from bone marrow versus peripheral blood. Dr. Anasetti reviews well-recognized data that show higher doses of CD34 cells protect against mortality. This information led Dr. Djulbegovic and collaborators to evaluate several published studies (total patients=1100) and report a meta-analysis to determine which product is better for a particular disease and for what reasons. He presents considerable significant detail. The conclusion is peripheral blood and bone marrow produce different products; the choice for a patient should be individualized, based on the ultimate goals of survival and quality of life.

Medium: Video Podcast
Method of Physician Participation: Electronic
Estimated time to complete the educational activity: 1 hour
Original Release: January 19, 2009
Termination Date: January 19, 2012

Author has no commercial interest relevant to this presentation.

A brief video preview of the program can be viewed below. Click the button to purchase and download the program.